

CUMULATIVE INDEX

VOLUME 24, NUMBERS 1-4, 1981

Abdominal incisions, 1176-1180
Abortion
 induced
 in adolescence, 982
 and genetic counselling, 1145-1146, 1158
 spontaneous
 and antenatal cytogenetic studies, 1033-
 1034
 in diabetic pregnancy, 150-151
Abscess, pelvic, management of, 1187-1196
Acetic acid, in vaginal secretions, 364-365
 in nonspecific vaginitis, 447
Acetylcholinesterase in amniotic fluid, in
 neural tube defects, 1092-1100
Acne, oral contraceptives affecting, 974, 992
ACTH activity, in aging, 176
Actinomycosis, pelvic inflammatory disease in,
 1236-1237
Adenocarcinoma, vaginal, 506-507
 from DES exposure in utero, 386-388
Adenosis, vaginal
 and carcinoma in situ, 495
 from DES exposure in utero, 381
Adipose tissue metabolism, in pregnancy,
 22-26
Adolescent contraception, 977-986
 abortion in, 982
 abstinence in, 980
 condoms and vaginal spermicidal agents in,
 981
 diaphragm in, 981-982
 and hazards of pregnancy, 979-980
 intrauterine device in, 982
 methods for, 980-985
 natural family planning in, 981
 oral contraceptives in, 982-985
 postcoital, 985
 and sex without intercourse, 980-981
 and sexuality in teenagers, 977-979
 withdrawal method in, 981

Adrenal gland
 activity in menopause, 187-188
 androstenedione secretion in, 257
 congenital hyperplasia of, antenatal
 diagnosis of, 1046, 1049
 oral contraceptives affecting, 971
Age
 maternal, and diabetes in pregnancy, 6-7
 of parents, and antenatal cytogenetic
 studies, 1025-1027, 1033
 and risks from oral contraceptives, 958-959
Aging, 165-178
 bone loss in, 203-217
 cellular changes in, 166-167, 173
 and cross links between collagen fibrils,
 167-169
 endocrine system in, 175-177
 and Hayflick phenomenon, 167, 171
 immune system in, 171-172
 neuroendocrine system in, 169-171
 neurologic changes in, 177-178
 organ function in, 173-175
 and psychologic symptoms in menopause,
 220-221
 structural changes with, 173
 time-clock theory of, 169-171
Albinism, prenatal diagnosis of, 1082
Alcohol
 for labor suppression, affecting infant, 677
 in pregnancy, affecting fetus, 778, 858
Alphaprodine in obstetric analgesia, affecting
 neonates, 652, 656
Amenorrhea, from oral contraceptives, 889,
 915, 943-948
Amino acids
 in amniotic fluid, 1045-1046
 in vaginal secretions, 357-359
Amniocentesis, 1007-1018
 in diagnosis of cardiovascular disease,
 859, 861

- Amniocentesis (*Continued*)
 and Rh sensitization, 1013-1015
 risks of, 1011-1013
 technical aspects of, 1008-1011
 timing of, 1008-1009
 in twin pregnancies, 1016-1017
 and ultrasound examination, 1009,
 1015-1016, 1106-1108
- Amnion nodosum, in diabetic pregnancy, 153
- Amniotic fluid
 acetylcholinesterase in, in neural tube
 defects, 1092-1100
 amino acids in, 1045-1046
 analysis of cells in
 cultured cells, 1047-1050
 uncultured cells, 1047
 composition of, 1008
 creatinine in, 74-75
 cultures of, and cytogenetic interpretation,
 1023-1025
 fatty acids in, and fetal lung maturity, 86
 α -fetoprotein testing in, 1089-1102
 insulin in, in diabetic pregnancy, 96
 lecithin-sphingomyelin ratio in, 75-78,
 551-552
 mucopolysaccharides in, 1046
 phosphatidylcholine in, 86, 111
 phosphatidylglycerol in, 80-84, 136
 steroid hormones in, 1046
 thyroid hormones in, 1046
- Amphetamines in pregnancy, affecting fetus,
 858
- Ampicillin, in *Gardnerella vaginalis* infection, 455
- Analgesia and anesthesia, obstetric, 519-677
 caudal anesthesia in, 605-606
 effects on labor, 611-612
 neurologic complications from, 613
 effects on newborn, 630, 631-632, 649-667
 in high-risk pregnancy, 671-677
 long-term effects, 662-666
 short-term effects, 651-662
 epidural block in, 567, 603-605. *See also*
 Epidural analgesia in obstetrics
 and fetal and neonatal physiology, 545-552,
 635-637
- general anesthetics in, 561-565, 625-632.
See also General anesthesia for
 obstetrics
 in high-risk pregnancy, 671-677
 inhalation agents in, 563-565, 620-625.
See also Inhalation analgesia in
 obstetrics
 local anesthetics in, 565-568, 587-594, 602-
 616. *See also* Regional anesthesia
 in obstetrics
- Analgesia and anesthesia, obstetric,
 local anesthetic in, (*Continued*)
 maternal awareness in, 630
 and maternal physiology, 525-540
 muscle relaxants in, 568-571
 narcotics in, 597-600
 paracervical block in, 567, 588-591
 parenteral agents in, 561-563
 and pharmacology of anesthetics, 561-571
 placental transfer of drugs in, 555-558
 and preparation for childbirth, 575-585
 and prevention of perinatal asphyxia,
 671-673
 pudendal block in, 567, 592-594
 and resuscitation of newborn, 635-647
 selection of procedures in, 521-524
 spinal anesthesia in, 567, 602-603
- Androgens
 plasma levels in menopause, 184-188
 and postmenopausal fractures, 210, 214
 production in breast cancer, 310-311
- Androstenedione
 conversion to estrone, 189, 194, 257, 307
 plasma levels in aging women, 185-186
 secretion in menopause, 257
- Anemia
 Fanconi, antenatal diagnosis of, 1032, 1082
 hemolytic, antenatal diagnosis of, 1064-1066
 iron deficiency, oral contraceptives af-
 fecting, 973, 990
 megaloblastic, from oral contraceptives, 973
 sickle cell. *See* Sickle cell disease
- Anencephaly
 and face presentations, 333-334
 and α -fetoprotein in amniotic fluid, 1089-
 1091
 in infants of diabetic mothers, 152
 ultrasonic diagnosis of, antenatal, 1110
- Anesthesia, obstetric. *See* Analgesia and
 anesthesia, obstetric
- Angina pectoris, in pregnancy, 785
- Antenatal diagnosis of disorders
 in adrenal hyperplasia, congenital, 1046,
 1049
 in albinism, 1082
 amniocentesis in, 1007-1018. *See also*
 Amniocentesis
 amniotic fluid cells in
 cultured, 1047-1050
 uncultured, 1047
 in argininosuccinicaciduria, 1045
 in ataxia-telangiectasia, 1081
 in Bloom's syndrome, 1032, 1081
 in cardiovascular disorders, 859, 861
 in Chediak-Higashi syndrome, 1083

Antenatal diagnosis of disorders (Continued)
 and confidentiality of family studies, 1143-1144, 1156
 in Conradi-Hunerman syndrome, 1083
 controversial requests for, 1143, 1160
 in cutis laxa, 1085
 in cystic fibrosis, 1046-1047
 in cystinosis, 1048
 in cytogenetic abnormalities, 1023-1037.
See also Cytogenetic studies, antenatal
 DNA analysis in, 1049-1050, 1056-1058
 in ectodermal dysplasia, hypohidrotic, 1084
 in Ehlers-Danlos syndrome, 1085
 in epidermolysis bullosa, 1075-1077, 1085, 1086
 in epidermolytic hyperkeratosis, 1077-1079
 ethical issues in, 1151-1166
 in Fabry's disease, 1084
 in Fanconi's anemia, 1082
 fetal blood sampling in, 1050-1051, 1058-1061
 fetal skin sampling in, 1072-1079
 α -fetoprotein testing in
 in amniotic fluid, 1089-1102
 in maternal serum, 1099-1100, 1103-1106, 1121-1131
 and ultrasound examination, 1103-1106
 fetoscopy in, 1069-1072
 in fucosidosis, 1084
 in glutaric aciduria, 1045
 in hemoglobinopathies, 1050, 1055-1062
 in hemolytic anemias, 1064-1066
 in hemophilias, 1062-1064
 in Hunter's syndrome, 1049
 in ichthyosis, 1072-1075, 1080, 1084
 and informed consent of screenees, 1137, 1154-1156
 and legal liability in genetic screening, 1133-1147
 in Menkes syndrome, 1080
 in metabolic disorders, 1041-1051
 in methylmalonic aciduria, 1045
 in mucopolysaccharidoses, 1046, 1048
 in Netherton syndrome, 1083
 in neural tube defects, 1089-1102
 in phenylketonuria, 1045-1046
 in Pompe's disease, 1047, 1049
 and problems with abortion, 1145-1146, 1158
 in Refsum's disease, 1084
 review questions on, 1169-1171
 risks of techniques in, 1139, 1158-1160
 in Sjogren-Larsson syndrome, 1080
 in skin disorders, hereditary, 1069-1086

Antenatal diagnosis of disorders (Continued)
 in Tay-Sachs disease, 1047, 1049
 in thyroid disease, 1046
 in trichothiodystrophy, 1083
 in tuberous sclerosis, 1086
 ultrasound in, 1093, 1103-1120
 with amniocentesis, 1009, 1015-1016, 1106-1108
 in Wiskott-Aldrich syndrome, 1082
 in xeroderma pigmentosum, 1081
Antiarrhythmic drugs, in pregnancy, 809-813
Anticholinergic agents, in obstetric analgesia, 571
Anticoagulant drugs, in pregnancy, 813-816, 826
 in pulmonary embolism, 770
 in venous thrombosis, 766-767
Anticonvulsants in pregnancy, affecting fetus, 839, 858
Antidiuretic hormone, activity in aging, 176
Aortia, coarctation in pregnancy, 730
Aortic valve
 bicuspid, in pregnancy, 728-729
 regurgitation in pregnancy, 729
 stenosis in pregnancy, 727-728, 780
Apgar scores
 anesthesia affecting, 631
 and face presentations, 343
 and resuscitation of newborn, 640-643
Argininosuccinicaciduria, antenatal diagnosis of, 1045
Arrhythmias
 diagnosis and management of, 803-805
 fetal, 839-841
 in pregnancy, 782-783
 cardioversion in, 809-813
 disopyramide in, 812
 procainamide in, 811
 propranolol in, 812-813, 858
 quinidine in, 811
 treatment of, 809-813
Arteritis in pregnancy, 829
Arthritis, rheumatoid, oral contraceptives affecting, 970
Ascites, and fetal arrhythmias, 841
Asphyxia, perinatal, 671-673
 in infants of diabetic mothers, 135
Aspiration
 in general anesthesia, 629
 meconium, 646-647
Ataxia-telangiectasia, prenatal diagnosis of, 1081
Atherosclerosis, and protective effect of estrogen therapy, 272-275
Atrial septal defect, in pregnancy, 732-734

- Atropine, in obstetric analgesia, 571
 Bacterial flora, vaginal, 360-361, 369, 446
 Barbiturates
 in obstetric analgesia, 561-562, 598
 effects on neonates, 651, 652, 653
 and perinatal asphyxia prevention, 672
 Behavior of neonates, obstetric anesthesia affecting, 631-632, 649-667
 Bicarbonate therapy, in resuscitation of newborn, 644
 Bilirubin, and hyperbilirubinemia in infants of diabetic mothers, 133
 Biopsy, endometrial, 290-292, 295-296
 Birth weight
 and brow presentations, 344
 and face presentations, 336
 Bladder, operative injuries of, 1275-1276
 Blood flow
 fetal, 545-548, 635-636
 drugs affecting, 672
 ultrasonographic evaluation of, 842-847
 regional, in pregnancy, 533
 renal, 533, 539
 uterine, 530-533, 556
 Blood pressure in pregnancy, 529, 699. *See also Hypertension; Hypotension*
 Blood volume in pregnancy, 526, 693-697
 Bloom's syndrome, antenatal diagnosis of, 1032, 1081
 Bone conditions. *See* Skeletal system
 Brain
 changes in aging, 177-178
 development of
 corticosteroids affecting, 138
 in infants of diabetic mothers, 152
 Breast
 cancer of
 and age at first pregnancy, 302
 androgen production in, 310-311
 anti-estrogen therapy in, 314
 and binding capacity of sex hormone-binding globulin, 308-310
 and delayed menopause, 303
 and dietary fat intake, 303
 epidemiologic and biochemical studies in, 302-306
 estriol levels in, 304-305
 estrogen receptors in, 313
 from estrogen therapy, 314-315
 estrone production in, 307
 in hypothyroidism, 311-312
 in males, estrogen-induced, 304
 ovarian hormones in genesis of, 303-304
 postmenopausal, estrogen therapy in, 314
 progesterone receptors in, 313
 Breast, cancer of (*Continued*)
 prolactin levels in, 311
 radiation-induced, 306
 and tryptophan metabolites in urine, 307
 development of, hormonal factors in, 301-302
 disease from oral contraceptives, 907-913
 Breech delivery, analgesia and anesthesia in, 523
 Brow presentations, 343-349
 course of labor in, 346-347
 diagnosis of, 345-346
 etiology of, 343-345
 management of, 347-348
 and perinatal mortality or morbidity, 348
 Budd-Chiari syndrome, from oral contraceptives, 957
 Bupivacaine, in obstetric analgesia, 567-568, 604
 effects on neonates, 657-658, 662
 toxic reactions to, 608
 Cadaverine, in vaginal discharge, 448, 449
 Calcitonin levels, in infants of diabetic mothers, 131
 Calcium
 excretion affected by estrogen, 210
 hypocalcemia in infants of diabetic mothers, 130-133
 in osteoporosis prevention, 214, 216
 Candidiasis, vulvar and vaginal, 424-430
 clinical features of, 424-425
 diagnosis of, 425-427
 treatment of, 427-430, 437
 Carbocaine, in obstetric analgesia, affecting neonates, 656
 Carbohydrates
 metabolism in diabetic pregnancy, 59-60
 in vaginal secretions, 359-360
 Carcinoma. *See* Tumors
 Cardiac output
 factors affecting, 791-795
 fetal, 556
 in pregnancy, 526-529, 697-699
 distribution of, 702-703
 exercise affecting, 705-706
 Cardiomegaly, in pregnancy, 737
 Cardiomyopathy
 in infants of diabetic mothers, 139
 in pregnancy, 737, 781, 826-827
 Cardiopathy, in diabetic pregnancy, 114-116
 Cardiovascular disorders
 anomalies in infants of diabetic mothers, 153
 fetal
 arrhythmias, 839-841
 in chromosomal disorders, 859

- Cardiovascular disorders, fetal** (*Continued*)
 diagnosis of, 859, 861
 familial predisposition to, 838, 852-853
 maternal disease as factor in, 153, 839
 and maternal drug ingestion, 839, 853-854, 857-858
 in mendelian disorders, 859-860
 multifactorial inheritance of, 851-857
 recurrence risk in, 855-856
 teratogens causing, 857-859
 ultrasonographic evaluation of, 837-847
 in pregnancy, 691-865
 acquired lesions in, 780-782
 activity recommendations in, 777
 antiarrhythmic drugs in, 809-813
 anticoagulant drugs in, 813-816, 826
 classification of, 774-776
 congenital heart disease, 780
 counseling in, 776-777
 diet recommendations in, 777
 digitalis glycosides in, 817-818
 diuretics in, 818-820
 evaluation of specific problems in, 722-740
 general anesthesia in, 628
 guidelines in management of, 773-786
 health priorities in, 776
 and hemodynamic monitoring, 795-797
 and hemodynamic physiology, 789-795
 and hemodynamic therapeutic options, 797-805
 infection control in, 777
 intratpartum management of, 789-806
 and maternal physiology, 693-707
 medications affecting, 778, 785
 and noninvasive assessment of function, 711-722
 question-related approach to, 778-779
 regional anesthesia in, 615-616
 review questions on, 863-865
 symptoms and signs of, 773-774
 therapeutic agents in, 809-820
 venous disorders in, 749-759
 venous dynamics in, 743-749
- Cardiovascular system**
 fetal, 545-548, 635-636
 in pregnancy, 525-533
- Cardioversion in arrhythmias**, in pregnancy, 809-811
- Carotid pulse tracings**, in pregnancy, 712-714
- Catecholamines**
 estrogen interaction with, 224-226, 235
 and hot flashes in menopause, 232, 235-237
 and psychologic symptoms in menopause, 222-226
- Catecholamines** (*Continued*)
 urinary, in infants of diabetic mothers, 127
- Caudal anesthesia in obstetrics**, 605-606
 effects on labor, 611-612
 neurologic complications from, 613
- Caudal dysplasia**, in infants of diabetic mothers, 151-159
- Cellular changes in aging**, 166-167, 173
- Cellular desquamate**, from vaginal epithelium, 357
- Central nervous system**. *See also Brain*
 anomalies in infants of diabetic mothers, 152
 oral contraceptives affecting, 966-970
- Cephalopelvic disproportion**
 and brow presentations, 344
 and face presentations, 336
- Cerebral vein thrombosis**, in pregnancy, 830-831
- Cerebrovascular disease**
 development after estrogen therapy, 276
 from oral contraceptives, 896, 955-956
 in pregnancy, 825-832
 arteritis in, 829
 atrial fibrillation in, 826
 cardiomyopathy in, 826-827
 in choriocarcinoma, 830
 in endocarditis, 828
 hypotension in, 827
 mitral valve prolapse in, 827
 paradoxical embolism in, 828
 in sickle cell disease, 829
 subarachnoid hemorrhage in, 832
 thrombosis of cerebral vein in, 830-831
 thrombotic thrombocytopenic purpura in, 829-830
- Cervical mucus**
 in mucorrhea, 430-432, 437
 properties of, 356-357
- Cervicitis**, 420-424
 clinical features of, 420-423
 treatment of, 423-424, 437
- Cervix uteri**
 abnormalities from DES exposure in utero, 831
 carcinoma of
 hysterectomy in, 1251-1252
 postmenopausal bleeding in, 286, 287
 changes from oral contraceptives, 918-922
- Cesarean section**
 and anesthetic agents affecting neonates, 658-659, 660, 661, 662
- Cesarean section**
 and anesthetic agents affecting neonates, 658-659, 660, 661, 662
 in diabetic pregnancy, 103

- Cesarean section, in
 diabetic pregnancy (*Continued*)
 and control of glucose levels, 60-62, 96
 with nephropathy, 112
 and respiratory distress syndrome in
 infants, 136-138
 effects on neonates, 675-676
 general anesthesia in, 626-627
 maternal hemodynamics during, 701-702
 spinal anesthesia in, 603
- Chediak-Higashi syndrome, prenatal**
 diagnosis of, 1083
- Chemotherapy, and antenatal diagnosis of**
 fetal disorders, 1034
- Cherney incision, 1179-1180**
- Chest x-ray in pregnancy, 712**
- Chlamydia trachomatis**
 cervicitis from, 420, 437
 and pelvic inflammatory disease, 1235-1236
- Chloasma, from oral contraceptives, 973-974**
- Chloroprocaine, in obstetric analgesia,**
 567-568, 604
 effects on neonates, 661, 662
 toxic reactions to, 608
- Cholesterol**
 metabolism in pregnancy, 35-38
 oral contraceptives affecting levels of, 934
- Chondrodysplasia puncta, prenatal diagnosis**
 of, 1083
- Choriocarcinoma**
 cerebral metastases in, 830
 oral contraceptives affecting, 923
- Chorionic cells, fetal, in maternal cervical**
 canal, 1036
- Chromatography**
 in nonspecific vaginitis, 447-448
 of odoriferous constituents of vaginal
 fluids, 363
 two-dimensional, for fetal lung maturity,
 80, 82
- Chromosome abnormalities**
 antenatal diagnosis of, 1023-1037
 cardiovascular anomalies in, 859
- Circadian rhythms, 170**
 for androstenedione, 185
 for dehydroepiandrosterone, 187
 for testosterone, 186
- Circulation. See Blood flow**
- Cleft lip or palate, in infants of diabetic**
 mothers, 153
- Climacteric**
 female, 253. *See also Menopause*
 in males, 176-177
- Clomiphene, in breast cancer, 314**
- Clonidine, in menopausal hot flashes, 238**
- Clotrimazole, in candidal vulvovaginitis,**
 427-430, 437
- Coarctation of aorta, in pregnancy, 730**
- Collagen, cross links between fibrils of, in**
 aging, 167-169
- Colposcopy, in condylomata acuminata,**
 465-466
- Conduction anesthesia in obstetrics. *See***
Regional anesthesia in obstetrics
- Condylomata acuminata, vaginal, 461-481**
 clinical significance of, 475-479
 colposcopy in, 465-466
 cytology of, 462-463
 differential diagnosis of, 489
 electron microscopy of, 467-475
 epidemiology of, 461-462
 histology of, 463-465
 in pregnancy, 481
 treatment of, 479-481
- Congenital anomalies, in infants of diabetic**
 mothers, 42-44, 140-141,
 149-156
- Connective tissue disease, oral contraceptives**
 affecting, 970-971
- Conradi-Hunerman syndrome, prenatal**
 diagnosis of, 1083
- Contraceptives**
 intrauterine
 for adolescents, 982
 and *Gardnerella vaginalis* infection, 457
 oral, 867-996. *See also* Oral contraceptives
- Contraction stress test, in diabetic**
 pregnancy, 99
- Corneal sensitivity, oral contraceptives**
 affecting, 970
- Coronary artery disease**
 development after estrogen therapy, 276
 in diabetic pregnancy, 114-116
- Coronary thrombosis, from oral contraceptives, 953-955**
- Corticosteroids**
 in provocative tests for glucose intolerance,
 14-15
 therapy in pregnancy
 and brain development in infants, 138
 and fetal lung maturity, 102, 138-139
- Cortisol**
 and breast development, 302
 excretion affected by estrogen, 210-212
 plasma levels in infants of diabetic mothers,
 128
- Cortisone provocative test, for glucose**
 intolerance in pregnancy, 14-15
- Corynebacterium vaginalis*. *See* Gardnerella**
vaginalis infection

- Counselling
in diabetes, 156-157
genetic, 1145-1146, 1158
- Creatinine
in amniotic fluid, 74-75
clearance of
aging affecting, 174
in diabetic nephropathy in pregnancy, 110
- Curare, hypotension from, 570
- Cutis laxa, prenatal diagnosis of, 1085
- Cystic fibrosis, antenatal diagnosis of, 1046-1047
- Cystinosis, antenatal diagnosis of, 1048
- Cytogenetic studies, antenatal, 1023-1037
indications for, 1025-1036
age of parents, 1025-1027, 1033
chromosomal breakage syndromes, 1032
chromosomal inversions, 1030-1032
chromosomal translocations, 1028-1030
chromosomal variants in parents, 1035
delayed fertilization or ovulation, 1035
exposure to radiation or chemotherapy, 1034
fetal growth retardation, 1035-1036
metabolic derangements in parents, 1034
previous child with autosomal trisomy, 1027-1028
previous stillborn or spontaneous abortuses, 1033-1034
X-linked recessive disorders, 1032
- Cytology
in condylomata acuminata, 462-463
in postmenopausal bleeding, 289-290
- Dehydroepiandrosterone levels, in menopause, 187-188
- Delivery
in brow presentations, 347-348
in diabetic pregnancy, 101-103
with nephropathy, 111-112
in face presentations, 338-339
hemodynamics in, 700-702
- Depression
and effects of oral contraceptives, 889-890, 966
postmenopausal, estrogen therapy in, 226
- Diabetes risk, with oral contraceptives, 930-932
- Diabetic pregnancy, 1-162, 675
affecting fetus, 839, 858
carbohydrate metabolism in, 59-60
cardiopathy in, 114-116
classification of, 4, 107
counseling in, 156-157
delivery in
method of, 103
- Diabetic pregnancy, delivery in (*Continued*)
in nephropathy, 111-112
regional anesthesia for, 615
timing of, 101-102
and detection of glucose intolerance, 10-16
clinical protocol for, 15-16
diagnosis of, 3-17
diet in, 56-57, 96
estriol assays in, 98-99
and fall in insulin requirements, 98
family history in, 6
fetal assessment in, 73-87, 97-100. *See also*
 Fetus, maturity tests
contraction stress test in, 99
and maternal assessment of fetal activity, 100
 nonstress test in, 99-100
fetal lung development in, 84-86
gestational diabetes, 3-17
glucose levels in, 13, 54-56
glycohemoglobins in, 65-71, 96
glycosuria in, 5-6
hospitalization versus outpatient care in, 100-101
hydramnios in, 98, 153
and infants of diabetic mothers, 125-142.
 See also Infants of diabetic mothers
insulin secretion in, 39-40
insulin therapy in, 57-58, 95-96
ketoacidosis in, 60
 treatment of, 62-63, 97
lecithin-sphingomyelin ratio in, 79-80
management of, 91-103
and maternal age, 6-7
maternal fuel metabolism in, 40-41
metabolic changes in, 38-44
metabolic control of, 51-63
 definition of, 52-56
in intrapartum period, 60-62, 96-97
objectives of, 58-59
mortality in
 maternal, 91-92
 perinatal, 92-93, 150-151
nephropathy in, 107-114
 delivery in, 111-112
 fetal evaluation in, 111
 neonatal complications in, 112-113
 postdelivery follow-up in, 113
 treatment of, 110
nocturnal hypoglycemia in, 60, 94, 128
pyelonephritis in, 98
and regulation of maternal blood glucose, 54-56, 93-97
after renal transplantation, 114

- Diabetic pregnancy (*Continued*)
 retinopathy with, 116-121
 nephropathy with, 110
 treatment of, 117-121
 review questions on, 161-162
 risk factors for, 4-10
 and screening for glucose tolerance, 7-10, 32
 stages of, 3-4
 teratogenic risk in, 42-44, 140-141,
 149-156
 vascular disease in, 107-121
 weight changes in, 38-39
- Diazepam, in obstetric analgesia, 599
 effects on neonates, 657, 659
- Diet
 in diabetic pregnancy, 56-57, 96
 fat intake as risk factor in breast cancer, 303
- Diethylstilbestrol exposure in utero
 cervical abnormalities from, 381
 and evaluation of offspring, 388-391
 uterine abnormalities from, 381-386
 vaginal lesions from, 379-383
 adenocarcinoma, 386-388
 benign abnormalities, 381
 embryologic aspects of, 381
 and treatment of offspring, 392-393
- Digitalis glycosides, in pregnancy, 817-818
- Discharge, vaginal
 causes of, 407-408
 mucoid or epithelial, 430-432
- Disopyramide, in arrhythmias in pregnancy, 812
- Diuretics, in pregnancy, 818-820
 in diabetic nephropathy, 110
- DNA analysis, in amniotic fluid cells, 1049-1050, 1056-1058
- DNCB therapy, in vaginal carcinoma in situ, 494
- L-Dopa, effects on aging, 170, 220-221
- Dopamine
 metabolism affected by estrogen, 224-225
 as neurotransmitter, 222
- Down's syndrome, antenatal diagnosis of, 1025-1029
- Drugs
 cardiovascular agents in pregnancy with heart disease, 809-820
 effects in pregnancy with heart disease, 778, 785
 maternal ingestion of, fetal reaction to, 839, 853-854, 857-858
 metabolism in aging, 175
 oral contraceptive agents. *See* Oral contraceptives
 teratogenic effects of, 155-156
- Ductus arteriosus patency, in pregnancy, 735
- Dyskeratocytes, in condylomata acuminata, 463, 469
- Dysmenorrhea, oral contraceptives in, 990-992
- Dysplasia
 caudal, in infants of diabetic mothers, 151-152
 ectodermal hypohidrotic, prenatal diagnosis of, 1084
- Echocardiography
 fetal, 837-842
 indications for, 838-841
 technique of, 841-842
 in pregnancy, 714-718, 786
- Ectodermal dysplasia, hypohidrotic, prenatal diagnosis of, 1084
- Education for childbirth, 575-585. *See also* Prepared childbirth
- Ehlers-Danlos syndrome
 collagen in, 169
 prenatal diagnosis of, 1085
- Eisenmenger syndrome, in pregnancy, 732
- Electrocardiography, in pregnancy, 712, 786
- Embolism
 paradoxical, in pregnancy, 828
 in pregnancy, 784
 pulmonary
 from oral contraceptives, 952
 in pregnancy, 762, 769-770
- Encephalocele, and α -fetoprotein in amniotic fluid, 1091
- Endocarditis, subacute bacterial, in pregnancy, 734-735, 784, 828
- Endocrine system
 aging affecting, 175-177
 disorders of
 oral contraceptives affecting, 971-972
 and psychologic symptoms in menopause, 221-227
- Endodermal sinus tumors, vaginal, 507
- Endometriosis
 hysterectomy in, 1251
 vaginal, 495
- Endometrium
 atrophy of, postmenopausal bleeding in, 286, 287
 biopsy of, 290-292, 295-296
 carcinoma of
 cytologic studies in, 290
 estrogen role in, 197-200, 213, 243-249, 275-276
 hysterectomy in, 1252
 management of, 296
 postmenopausal bleeding in, 286, 287

- Endometrium (Continued)**
- estrogen in, 197-200
 - hyperplasia of
 - and breast cancer, 312
 - cytologic studies in, 290
 - management of, 296-297
 - oral contraceptives affecting, 917, 990
 - postmenopausal bleeding in, 286, 287, 293-294
 - oral contraceptives affecting, 874-875
 - polyps of, postmenopausal bleeding in, 292, 296
 - management of, 297
 - tumors from oral contraceptives, 915-918
- Enflurane**, in obstetric anesthesia, 564-565, 623
- Environmental factors** in congenital heart disease, 851-857
- Enzymes**
- in amniotic fluid cells, 1047-1048
 - defects in fetal erythrocytes, diagnosis of, 1065-1066
- Epidermolysis bullosa**, antenatal diagnosis of, 1075-1077, 1085, 1086
- Epidermolytic hyperkeratosis**, antenatal diagnosis of, 1077-1079
- Epidural analgesia** in obstetrics, 567, 603-605
 - catheter complications with, 611
 - effects on labor, 611
 - effects on neonates, 655, 656, 657-660, 661, 662
 - failure of, 609-611
 - neurologic complications from, 613
- Epilepsy**
- maternal, affecting fetus, 839
 - oral contraceptives affecting, 969
- Epinephrine**, in resuscitation of newborn, 645
- Erythema**
- multiforme, oral contraceptives affecting, 971
 - nodosum, oral contraceptives affecting, 971
- Estradiol**
- conversion from testosterone, 189, 194
 - plasma levels
 - aging affecting, 181-182
 - in breast cancer, 305
 - postmenopausal, 188-189, 256-257
 - postmenopausal production of, 307
- Estradiol levels**
- in breast cancer, 304-305
 - in diabetic pregnancy, 98-99
 - with nephropathy, 111
- Estrogen**
- affecting vaginal epithelium, 360
 - anti-estrogen therapy in breast cancer, 314
- Estrogen (Continued)**
- and breast development, 301-302
 - deficiency of
 - and hot flashes in menopause, 231-237
 - and loss of bone density, 203-217
 - and psychologic symptoms in menopause, 219-227
 - and endometrial cancer development, 197-200, 213, 243-249, 275-276
 - biologic plausibility of, 243-244
 - epidemiologic studies of, 245-248
 - incidence of, 244-245
 - in endometrium, 197-200
 - extraglandular formation of, 190, 193-197, 244, 306
 - increased, clinical conditions with, 196-197
 - interaction with catecholamines, 224-226, 235
 - in oral contraceptives. *See Oral contraceptives*
 - plasma levels in menopause, 188-190
 - postmenopausal secretion of, 193-200
 - production and transport of, 306-310
 - and psychologic symptoms in menopause, 226-227
 - receptor activity, 198-199, 200
 - in breast cancer, 313
 - therapy with
 - advantages and benefits of, 266-275
 - in atherosclerosis prevention, 272-275
 - in atrophic genitourinary cancer, 267-269, 433-434
 - in bone loss prevention, 205-217, 269-272
 - and breast cancer development, 314-315
 - disadvantages and risks of, 275-277
 - dosage in, 277
 - in dysfunctional uterine bleeding, 275
 - in hot flashes, menopausal, 237-238, 266-267
 - in menopause, 253-280
 - in postmenopausal breast cancer, 314
 - in postmenopausal depression, 226
 - progestins with, 213-216, 248
 - recommendations for use of, 277-280
 - thromboembolism from, 276-277
- Estrone**
- conversion from androstenedione, 189, 194, 257, 307
 - postmenopausal production of, 189, 257, 307
- Ethical issues**, in genetic screening and antenatal diagnosis, 1151-1166
- Etidocaine**, in obstetric anesthesia, 568
 - effects on neonates, 662

- Exercise, in pregnancy, 704-707
and fetal health, 706-707
- Eyes
oral contraceptives affecting, 956, 970
retinopathy in diabetic pregnancy, 116-121
- Fabry's disease, prenatal diagnosis of, 1084
- Face presentations, 333-343
course of labor in, 338-339
diagnosis of, 337-338
etiology of, 333-337
management of, 339-341
and perinatal mortality or morbidity, 341-343
- Fallopian tubes, oral contraceptives affecting, 873-874
- Fallot tetralogy, in pregnancy, 732
- Fanconi's anemia, antenatal diagnosis of, 1032, 1082
- Fat
intake as risk factor in breast cancer, 303
mobilization in pregnancy, 34-35
storage in pregnancy, 22-26
in diabetic pregnancy, 38-39
- Fatty acids in amniotic fluid, and fetal lung maturity, 86
- Fertilization, delayed, and chromosomal abnormalities, 1035
- Fetal cells, lipid staining of, as fetal maturity test, 74
- α -Fetoprotein
in amniotic fluid, 1089-1102
in maternal serum, 1099-1100, 1103-1106, 1121-1131
- Fetoscopy, 1069-1072
risks of, 1071
and skin sampling, 1072-1079
- Fetus
antenatal diagnosis of disorders in. *See* Antenatal diagnosis of disorders arrhythmias in, 839-841 blood sampling for diagnosis of disorders, 1050-1051, 1058-1061 cardiovascular system in, 545-548, 635-636 disorders of. *See* Cardiovascular disorders, fetal distressed, and regional anesthesia use, 614 face and brow presentations of, 333-349 growth retardation of and antenatal chromosome studies, 1035-1036 in diabetic nephropathy, 111 infants of diabetic mothers. *See* Infants of diabetic mothers lung development in corticosteroids affecting, 102, 138-139
- Fetus, lung development in (*Continued*)
in diabetic pregnancy, 84-86
macrosomia in diabetic pregnancy, 41-42, 94, 139-140
maternal drug ingestion affecting, 839, 853-854, 857-858
maternal exercise affecting, 706-707
maturity tests
creatinine in amniotic fluid, 74-75
in diabetic nephropathy, 111
in diabetic pregnancy, 73-87, 97-110
fatty acid analysis, 86
lecithin-sphingomyelin ratio in amniotic fluid, 75-78, 111, 136
lipid staining of fetal cells, 74
new assays in, 86-87
phosphatidylcholine in amniotic fluid, 86, 111
phosphatidylglycerol in amniotic fluid, 80-84, 136
rapid surfactant test, 78-79
roentgenography, 74
two-dimensional chromatography, 80, 82
ultrasonography, 75, 100
physiology of, 545-552, 635-637
pulmonary function in, 549-552, 636-637
skin sampling in, 1072-1079
ultrasonography of
for cardiac anatomy, 837-842
for vascular dynamics, 842-847
- Fibroblasts, fetal, in antenatal diagnosis of disorders, 1047-1048, 1057
- Fistulas, vaginal, 408
- Fluid balance, maternal, and neonatal problems, 674
- Fluoride therapy, effects in postmenopausal women, 214
- 5-Fluorouracil, in vaginal carcinoma *in situ*, 492-494
- Foam test for fetal maturity, 78
- Follicle-stimulating hormone levels aging affecting, 181-182
in menopausal hot flashes, 233
oophorectomy affecting, 232
postmenopausal, 254-256
- Forceps delivery, analgesia and anesthesia in, 523
- Fractures, postmenopausal after androgen therapy, 210 prevention with estrogen therapy, 207-209, 214, 269-272
- Fucosidosis, prenatal diagnosis of, 1084
- Gallamine, in obstetric anesthesia, 570
- Gardnerella vaginalis* infection, 374, 407, 411-412, 439-458

- Gardnerella vaginalis* infection (Continued)
- and amines in vaginal discharge, 448
 - clinical diagnosis of, 451-454
 - clue cells in, 450-451
 - and concomitant organisms, 445-448
 - culture isolation of bacteria in, 442-443
 - invasiveness of, 456-457
 - male role in, 456
 - prevalence of, 443-445
 - symptoms and signs of, 449
 - treatment of, 374, 411, 437, 454-456
 - trichomonas infection with, 455-456
 - vaginal odor in, 374, 411, 445, 448, 450
- Gastrointestinal tract
- anomalies in infants of diabetic mothers, 153
 - changes in pregnancy, 538-539
 - oral contraceptives affecting disorders in, 972
 - ultrasonic diagnosis of anomalies in, antenatal, 1114-1116
- Gastroschisis, ultrasonic diagnosis of, antenatal, 1115
- General anesthesia for obstetrics, 561-565, 625-632
- aspiration risk in, 629
 - in cesarean section, 626-627
 - effects on neonates, 655
 - maternal ventilation in, 629-630
 - in prematurity, 629
 - uterine relaxation from, 627
 - in vaginal delivery, 625-626
- Genetic disorders, antenatal diagnosis of. *See* Antenatal diagnosis of disorders
- Genetic factors
- in congenital heart disease, 851-857
 - in malformations in children of diabetic parents, 154
- Genitourinary tract
- atrophic changes in menopause, estrogen therapy in, 267-269
 - malformations in infants of diabetic mothers, 153
- Gestational diabetes, 3-17
- Glomerulosclerosis, in diabetic pregnancy, 108
- Glucagon
- plasma levels in infants of diabetic mothers, 128
 - secretion in pregnancy, 31-32
- Glucose
- assimilation in pregnancy, 32-34
 - excretion in pregnancy, 539
 - hyperglycemia as cause of congenital malformations, 155
 - hypoglycemia as cause of congenital malformations, 155
- Glucose, hypoglycemia (Continued)
- in infants of diabetic mothers, 125-130
 - nocturnal, in diabetic pregnancy, 60, 94, 128
 - maternal levels of, affecting infant, 674-675
 - metabolism affected by oral contraceptives, 927-932
 - plasma levels in diabetic pregnancy, 54-56
 - regulation of, 54-56, 93-97
 - tolerance tests
 - aging affecting, 177
 - and detection of intolerance in pregnancy, 10-16
 - in gestational diabetes, 3-4
 - and glycosuria in pregnancy, 5-6
 - intravenous, 13-14
 - oral, 12-13
 - risk factors for, 5
 - as screening test in pregnancy, 7-10, 32
 - and single blood glucose levels, 10-11
 - and steroid provocative tests, 14-15
- Glutaric acidemia, antenatal diagnosis of, 1045
- Glycogen, vaginal, 360, 369
- Glycohemoglobins, in diabetic pregnancy, 65-71, 96
- Glycopyrrolate, in obstetric analgesia, 571
- Glycosuria in pregnancy, and gestational diabetes, 5-6
- Gonadotropin releasing hormone, response to, in amenorrhea, 946-947
- Gonorrhea, cervicitis in, 420, 437
- Gracilis muscle flap transposition, 1280-1282
- Growth hormone
- and breast development, 302
 - plasma levels in infants of diabetic mothers, 128
- Growth retardation, intrauterine and antenatal chromosome studies, 1035-1036
- in diabetic nephropathy, 111
- Haemophilus vaginalis*. *See* *Gardnerella vaginalis* infection
- Halothane, in obstetric anesthesia, 564-565, 623
- Harlequin ichthyosis, antenatal diagnosis of, 1072-1075
- Hayflick phenomenon, in aging, 167, 171
- Headaches
- oral contraceptives affecting, 968-969
 - from regional anesthesia, 607
- Heart
- cardiomyopathy in infants of diabetic mothers, 139

- Heart (Continued)**
- congenital disease of. *See* Cardiovascular disease, fetal
 - diabetic cardiopathy in pregnancy, 114-116
 - disease in pregnancy, 691-865. *See also* Cardiovascular disease, in pregnancy
 - failure in pregnancy, 783-784
 - fetal
 - development of, 547, 635
 - ultrasonography of, 837-842
 - myocardial infarction
 - in diabetic pregnancy, 114-116
 - from oral contraceptives, 896-897
 - and protective effect of estrogen therapy, 272-275
 - in pregnancy, 525-526
- Heat loss in neonates**, 638
- Hematocrit**, in infants of diabetic mothers, 134
- Hematologic problems**, in infants of diabetic mothers, 133-135
- Hemodynamic physiology**, 789-795
- in labor and delivery, 700-702
 - monitoring of, 795-797
 - in pregnancy, 697-699
 - exercise affecting, 705-706
 - and therapeutic options, 797-805
- Hemoglobin**
- A₁ type in diabetic pregnancy, 65-71, 96
 - composition of, 1055-1056
- Hemoglobinopathies**, antenatal diagnosis of, 1050, 1055-1062
- amniotic fluid cell DNA in, 1056-1058
 - fetal blood analysis in, 1058-1061
 - and maternal screening programs, 1061-1062
- Hemolytic anemia**, antenatal diagnosis of, 1064-1066
- Hemophilia**, antenatal diagnosis of, 1062-1064
- Hemophilus vaginalis***. *See* *Gardnerella vaginalis* infection
- Hemorrhage**
- obstetric, anesthesia in, 615, 628
 - subarachnoid, in pregnancy, 832
- Hemorrhoids**, in pregnancy, 758-759
- Heparin therapy** in pregnancy, 814-816, 826
 - in pulmonary embolism, 770
 - in venous thrombosis, 766-767
- Hepatic vein occlusion**, from oral contraceptives, 957
- Herpes simplex**, cervicitis from, 420, 437
- High-risk pregnancy**, obstetric anesthesia in, 671-677
- Holter monitoring**, in pregnancy, 712
- Homocystinuria**, collagen in, 169
- Hot flashes**, in menopause, 231-239
- Hunter's syndrome**, antenatal diagnosis of, 1049
- Hydergine**, effects on aging, 170
- Hydramnios**, in diabetic pregnancy, 98, 153
- Hydrocarbons**, fetal reactions to, 853
- Hydrocephalus**
- and α -fetoprotein in amniotic fluid, 1091
 - ultrasonic diagnosis of, antenatal, 1110-1113
- Hypertension**
- from oral contraceptives, 893-895
 - in pregnancy, 781
 - and regional anesthesia use, 614
 - pulmonary, in pregnancy, 731-732, 784
- Hyperventilation**, in pregnancy, 704
- Hypocalcemia**, in infants of diabetic mothers, 130-133
- Hypotension**
- neonatal, 645-646
 - in pregnancy, 785
 - cerebral blood flow in, 827
 - from regional anesthesia, 603, 606
 - in supine position during labor, 528
- Hypothalamus**, oral contraceptives affecting, 870-871
- Hypothyroidism**, and breast cancer, 311-312
- Hysterectomy**
- abdominal, and prevention of postoperative infections, 1259-1266
 - in benign diseases, 1249-1251
 - indications for, 1245-1258
 - appropriate, 1249-1254
 - inappropriate, 1254-1255
 - in neoplastic disease, 1251-1253
 - and removal of normal uterus, 1256
 - second opinions on, 1247-1248
 - for sterilization, 1253-1254
 - vaginal vs abdominal approach in, 1255
 - vaginal vault prolapse after, repair of, 1217-1225
- Ichthyosis**, antenatal diagnosis of, 1072-1075, 1080, 1084
- Immune system**, age-related changes in, 171-172
- Immunizations**, prior to pregnancy, 777
- Immunologic diseases**, oral contraceptives affecting, 970-971
- Incisions**, abdominal, 1176-1180
- Cherny, 1179-1180
 - gridiron, 1180
 - lower midline, 1178
 - McBurney, 1180

- Incisions, abdominal (*Continued*)
 muscle splitting, transverse, 1179
 paramedian, 1178-1179
 pararectus, 1179
 Pfannenstiel, 1179
 transverse, 1179-1180
 vertical, 1177-1179
- Indomethacin for labor suppression, affecting infant, 676
- Infants of diabetic mothers, 125-142
 birth asphyxia in, 135
 cardiomyopathy in, 139
 cardiovascular anomalies in, 153
 caudal dysplasia in, 151-152
 central nervous system anomalies in, 152
 congenital anomalies in, 42-44, 140-141, 149-156
 incidence of, 141, 149-150
 and mechanisms in teratogenesis, 154-156
 and perinatal or fetal mortality, 150-151
 types of, 151-154
 gastrointestinal anomalies in, 153
 genitourinary anomalies in, 153
 hematologic problems in, 133-135
 hyperbilirubinemia in, 133
 hypocalcemia in, 130-133
 hypoglycemia in, 125-130
 treatment of, 129-130
 lipid metabolism in, 130
 macrosomia in, 41-42, 94, 139-140
 magnesium deficiency in, 131
 metabolic problems in, 125-133
 morphologic and functional problems in, 139-141
 nephropathy affecting, 112-113
 polycythemia in, 134-135
 prognosis of, 141-142
 renal vein thrombosis in, 135
 respiratory distress syndrome in, 136-139
 treatment of, 138-139
 skeletal anomalies in, 151-152
- Infarction, myocardial
 in diabetic pregnancy, 114-116
 from oral contraceptives, 896-897
 and protective effect of estrogen therapy, 272-275
- Inhalation analgesia in obstetrics, 563-565, 620-625
 clinical uses of, 620
 drugs in, 564, 622-623
 environmental pollution from, 565, 625
 fetal safety with, 624
 maternal safety with, 623-624
 and progress of labor, 625
- Inhalation analgesia in obstetrics (*Continued*)
 techniques for, 620-622
- Insulin
 in amniotic fluid, in diabetic pregnancy, 96
 and breast development, 302
 plasma levels of
 in infants of diabetic mothers, 126
 oral contraceptives affecting, 927-928
 receptors for, in infants of diabetic mothers, 27-31, 139-140
- requirements in diabetic pregnancy, 98
 secretion of
 aging affecting, 177
 in diabetic pregnancy, 39-40
 in pregnancy, 26-31
 therapy in diabetic pregnancy, 57-58, 95-96
 in intrapartum period, 61, 96-97
- Intestinal anomalies, in infants of diabetic mothers, 153
- Intrauterine contraceptive devices for adolescents, 982
 and *Gardnerella vaginalis* infection, 457
- Iron deficiency anemia, oral contraceptives affecting, 973, 990
- Isoflurane, in obstetric anesthesia, 564, 623
- Isoxuprene in pregnancy, affecting infant, 676
- Jaundice, in infants of diabetic mothers, 133
- Ketamine, in obstetric anesthesia, 562-563, 599
 effects on neonates, 660, 661
- Ketoacidosis in diabetic pregnancy, 60
 treatment of, 62-63, 97
- Ketone body metabolism, in pregnancy, 34-35
- Kidney
 aging affecting, 174-175
 anomalies in infants of diabetic mothers, 153
 diseases of, oral contraceptives affecting, 972-973
- nephropathy in diabetic pregnancy, 107-114
 in pregnancy, 539-540
 transplantation of, diabetic pregnancy after, 114
- Koilocytes, in condylomata acuminata, 462-463, 469
- Labor
 analgesia and anesthesia in, 519-677. *See also* Analgesia and anesthesia, obstetric
 in brow presentations, 346-347
 in diabetic pregnancy, 101-103
 and control of glucose levels, 60-62, 96
 in face presentations, 338-339
 hemodynamics in, 700-702
 and hypotension in supine position, 528

- Labor (Continued)**
 and prepared childbirth, 575-585. *See also* Prepared childbirth
 suppression of, affecting infant, 676-677
- Lactic acid, vaginal**, 330, 365, 369
- ratio to succinic acid, in nonspecific vaginitis**, 447-448
- Lamaze method for prepared childbirth**, 580-582
- Lecithin-sphingomyelin ratio in amniotic fluid**, 75-78, 551-552
- Borer modification of**, 78
 in diabetic pregnancy, 79-80, 136
 in nephropathy, 111
- Legal liability in genetic screening**, 1133-1147
- Leiomyosarcomas of vagina**, 507
- Lergotrile mesylate**, effects on aging, 170
- Levamisole**, in condylomata acuminata, 480
- Lidocaine**, in obstetric analgesia, 567-568, 603, 604
 effects on neonates, 656
- Lip, cleft**, in infants of diabetic mothers, 153
- Lipid**
 in fetal cells, staining of, 74
 metabolism of
 in infants of diabetic mothers, 130
 oral contraceptives affecting, 932-936
 in pregnancy, 35-38
- Lipoprotein metabolism**, in diabetic pregnancy, 40-41
- Lithium** in pregnancy, affecting fetus, 858
- Liver**
 diseases of, oral contraceptives affecting, 972
 tumors from oral contraceptives, 913-915
- Local anesthesia in obstetrics**, 565-568, 587-594, 602-616. *See also* Regional anesthesia in obstetrics
- Lumbar epidural block** in obstetrics, 567, 603-605. *See also* Epidural analgesia in obstetrics
- Lumbar sympathetic block** in obstetrics, 567
- Lung**
 aging affecting, 174
 fetal, 549-552, 636-637
 corticosteroids affecting, 102, 138-139
 development in diabetes, 84-86
 tests for maturity of, 75-86
 volumes in pregnancy, 534
- Lupus erythematosus**
 oral contraceptives affecting, 971
 in pregnancy, 829
 affecting fetus, 858
- Luteinizing hormone level**
 aging affecting, 181-182
- Luteinizing hormone level (Continued)**
 catecholamines affecting, 224
 in menopausal hot flashes, 233-234
 midcycle surge of, 194
 oophorectomy affecting, 232
 postmenopausal, 254-256
- Lymphocytes, fetal**, in maternal blood, 1036
- Macrosomia**, in infants of diabetic mothers, 41-42, 94, 139-140
- Magnesium deficiency**, in infants of diabetic mothers, 131
- Magnesium sulfate**
 for labor suppression, affecting infant, 677
 muscle relaxants with, 571
- Malformations**
 cardiac, from teratogenic agents, 857-859
 in infants of diabetic mothers, 42-44, 140-141, 149-156
- Marfan's syndrome**
 cardiac disease in, 860
 in pregnancy, 729-730, 780, 781
- McBurney incision**, 1180
- Meconium aspiration syndrome**, 646-647
- Medroxyprogesterone acetate**, in menopausal hot flashes, 238, 267
- Melanomas of vagina**, 507-508
- Mendelian disorders**, cardiac disease in, 859-860
- Menkes syndrome**
 copper deficiency in, 169
 prenatal diagnosis of, 1080
- Menopause**, 163-324
 age of, 203, 253
 and aging process, 165-178
 androgen levels in, 184-188
 delayed, and breast cancer risk, 303
 endocrinologic changes in, 254-266
 and estrogen-induced endometrial cancer, 243-249
- estrogen levels in, 188-190
 estrogen replacement therapy in, 253-280
- extraglandular estrogen formation in**, 193-197
- hot flashes in**, 231-239
 catecholamine basis for, 232, 235-237
 estrogen therapy in, 266-267
 pathophysiology of, 231-235
 treatment of, 237-238
- neuroendocrine mechanisms in**, 169-170
- osteoporosis in**, 203-217
- ovary after**, 181-190
- ovary and postmenopausal bleeding**, 285-298
 in atrophic vaginitis, 286, 297
 causes of, 285-289
 cytologic studies in, 289-290

- Menopause, and postmenopausal bleeding (*Continued*)
 dilation and curettage in, 286-287, 289, 296
 endometrial biopsy in, 290-292, 295-296
 in endometrial hyperplasia, 286, 287, 292-294
 management of, 294-298
 recurrent, 292, 298
 psychologic symptoms in, 219-227
 and endocrine dysfunction, 221-227
 review questions on, 323-324
- Menorrhagia, oral contraceptives in, 989-990
- Menstrual cycle
 vaginal odors in, 365-366
 vaginal secretions in, 356-357
- Menstruation, and toxic shock syndrome, 402-404
- Meperidine, in obstetric analgesia, 597-598
 effects on neonates, 651, 652, 653, 655, 656, 657, 659, 661
- Mepivacaine, in obstetric analgesia, 567-568, 604
- Mesenteric thrombosis, from oral contraceptives, 956-957
- Mestranol, prophylactic, to prevent bone loss, 205-206
- Metabolic control of diabetic pregnancy, 51-63
- Metabolism
 in diabetic pregnancy, 38-44
 disorders in
 antenatal diagnosis of, 1041-1051
 in infants of diabetic mothers, 125-130
 in normal pregnancy, 22-38
 oral contraceptives affecting, 927-939
- Methoxyflurane, in obstetric anesthesia, 564-565, 623
 effects on neonates, 659
- Methylmalonic acidemia, antenatal diagnosis of, 1045
- Metocurine, in obstetric anesthesia, 570
- Metronidazole
 carcinogenic effects of, 456
 effects in pregnancy, 415-416, 419-420
 in *Gardnerella vaginalis* vaginitis, 374, 411, 437
 with trichomoniasis, 455-456
 in *Trichomonas vaginalis* vaginitis, 418-420, 437
- Metrorrhagia, oral contraceptives in, 990
- Miconazole, in candidal vulvovaginitis, 427-430, 437
- Microcephaly, ultrasonic diagnosis of, antenatal, 1113-1114
- Microflora, vaginal, 360-361, 369, 446
- Mitral valve
 prolapse in pregnancy, 724-727, 781, 827
 regurgitation in pregnancy, 724
 stenosis in pregnancy, 722-724, 780
- Monitoring, fetal, in face presentations, 342-343
- Monoamine oxidase activity, estrogen affecting, 225
- Morphine in obstetric analgesia, effects in neonates, 651-652, 656
- Mortality
 in diabetic pregnancies
 maternal, 91-92
 perinatal, 92-93, 150-151
 perinatal
 in brow presentations, 348
 in face presentations, 341-342
- Mucopolysaccharidoses, antenatal diagnosis of, 1046, 1048
- Mucorrhea, 430-432, 437
- Mucus, cervical, properties of, 356-357
- Müllerian ducts, DES exposure affecting, 381
- Multiple pregnancy. *See* Twin pregnancies
- Muscle and musculocutaneous flaps, in gynecologic surgery, 1277-1316
- Muscle relaxants, in obstetrics, 568-571
- Mycoplasmas, and pelvic inflammatory disease, 1236
- Myocardial infarction
 in diabetic pregnancy, 114-116
 from oral contraceptives, 896-897
 and protective effect of estrogen therapy, 272-275
- Myomas, uterine
 from oral contraceptives, 918
 postmenopausal bleeding in, 186
- Myometrium, estrogen in, 197-198
- Nafoxidine, in breast cancer, 314
- Naloxone, as narcotic antagonist, 600
 maternal prophylactic administration of, 660-661
 in neonates, 645
- Narcotic analgesia in obstetrics, 597-600
- Natural childbirth, 567-578
- Neonates
 of diabetic mothers, 675. *See also* Infants of diabetic mothers
 initiation of breathing in, 551, 636-637
 maternal fluid balance affecting, 674
 obstetric analgesia and anesthesia affecting, 630, 631-632, 649-667
 in high-risk pregnancy, 671-677
 long-term effects, 662-666
 short-term effects, 651-662

- Neonates (Continued)**
- parental interactions with, 654-655, 656-657
 - physiology of, 545-552, 635-638
 - resuscitation of, 635-647, 673. *See also* Resuscitation of newborn
 - thermoregulation in, 637-638, 673-674
- Nephropathy** in diabetic pregnancy, 107-114
- Netherton syndrome**, prenatal diagnosis of, 1083
- Neural tube defects**
- in infants of diabetic mothers, 152
 - prenatal diagnosis of, 1089-1102, 1121-1131
- Neurobehavior of neonates**, obstetric analgesia affecting, 631-632, 649-667
- Neuroendocrine system**
- in aging process, 169-171
 - and psychologic symptoms in menopause, 221-227
- Neurologic system**, aging affecting, 177-178
- Newborn.** *See* Neonates
- Nitrous oxide** for obstetric analgesia, 622-623
- Norepinephrine**, as neurotransmitter, 222
- Nuccal cord**
- in brow presentations, 343
 - in face presentations, 337
- Nutrition.** *See* Diet
- Obesity**, and binding capacity of sex hormone-binding globulin, 308-310
- Obstetric analgesia and anesthesia.** *See* Analgesia and anesthesia, obstetric
- Odors, vaginal**, 361-370
- Omphalocele**, ultrasonic diagnosis of, antenatal, 1115
- Oophorectomy**
- and atherosclerosis development, 273
 - hot flashes after, 231, 232
 - treatment of, 237-238
 - and plasma levels of estrone, 257
 - protective effect against breast cancer, 303-304
- Oral contraceptives**, 867-996
- and acids in vaginal secretions, 365
 - in acne, 974, 992
 - in adolescence, 982-985. *See also* Adolescent contraception
 - and age of users, 958-959
 - amenorrhea from 889, 915, 943-948
 - duration of, 945
 - endocrinology of, 945-946
 - factors related to, 944-945
 - progesterone challenge test in, 946
 - and responses to estrogen and clomiphene citrate, 947
 - ovaries affected by, 873
 - oviducts affected by, 873-874
 - peripheral effects of, 873-875
 - pharmacokinetics of, 881-884
 - pituitary affected by, 871-872
 - postcoital, 985
 - preparations available, 879-881
 - retinal vascular occlusion from, 956, 970
- Oral contraceptives, amenorrhea from (Continued)**
- and responses to gonadotropin releasing hormone, 946-947
 - and return of ovulation or menstruation, 947-948
 - biologic potencies of, 885-886
 - breakthrough bleeding from, 888-889
 - and breast cancer development, 315
 - cerebrovascular disease from, 896, 955-956
 - choice of, 886-887
 - clinical pharmacology of, 879-887
 - complications from, 893-897
 - contraindications to, 897-899
 - coronary thrombosis from, 953-955
 - depression from, 889-890, 966
 - and diabetes development, 930-932
 - dosage of, 957-958
 - duration of use, 960, 988-989
 - in dysmenorrhea, 990-992
 - in endometrial hyperplasia, 917, 990
 - endometrium affected by, 874-875
 - hepatic vein occlusion from, 957
 - hypertension from, 893-895
 - hypothalamus affected by, 870-871
 - interaction with other drugs, 966
 - in iron deficiency anemia, 973, 990
 - mechanism of action, 869-875
 - in menorrhagia, 989-990
 - mesenteric thrombosis from, 956-957
 - metabolic effects of, 927-939
 - glucose metabolism, 927-932
 - lipid metabolism, 932-936
 - protein metabolism, 936-939
 - in metrorrhagia, 990
 - myocardial infarction from, 896-897
 - nausea and vomiting from, 888
 - and neoplasia risk, 902-923
 - breast disease, 907-913
 - cervical changes, 918-922
 - choriocarcinoma, 923
 - endometrial tumors, 915-918
 - investigative methods in, 904-907
 - liver tumors, 913-915
 - ovarian disease, 922-923
 - pituitary tumors, 915
 - noncontraceptive uses of, 987-992
 - ovaries affected by, 873
 - oviducts affected by, 873-874
 - peripheral effects of, 873-875
 - pharmacokinetics of, 881-884
 - pituitary affected by, 871-872
 - postcoital, 985
 - preparations available, 879-881
 - retinal vascular occlusion from, 956, 970

- Oral contraceptives (Continued)**
- review questions on, 995-996
 - and screening of potential users, 899-900
 - side effects of, 887-891
 - smoking as risk factor with, 895, 896, 897, 899-900
 - and surgical risks, 960
 - systemic effects of, 966-974
 - in adolescence, 983-984
 - in central nervous system, 966-970
 - in depression, 889-890, 966
 - in endocrine disorders, 971-972
 - in epilepsy, 969
 - in eye, 956, 970
 - in gastrointestinal disorders, 972
 - in headaches, 968-969
 - in hemopoietic disorders, 973
 - in immunologic and connective tissue diseases, 970-971
 - in liver disease, 972
 - in lupus erythematosus, 971
 - in multiple sclerosis, 970
 - in renal disease, 972-973
 - in rheumatoid arthritis, 970
 - skin changes from, 973-974
 - in vaginitis, 973
 - in Wilson's disease, 968
 - thromboembolism from, 895-896, 952-953
 - use with medical disorders, 965-974
 - vascular effects of, 951-962
 - pathogenesis of, 960-961
 - weight change from, 890-891
- Osteoporosis in menopause, 203-217
- estrogen therapy in, 269-272
- Ovaries
- hormones of, and breast cancer risk, 303-304
 - menopause affecting, 184-190
 - neoplasia from oral contraceptives, 922-923
 - oral contraceptives affecting, 873
 - in perimenopause, 181-184
 - Oviducts, oral contraceptives affecting, 873-874
- Ovulation
- delayed, and chromosomal abnormalities, 1035
 - and vaginal odors, 355
 - and vaginal secretions, 357
- Oxytocin
- challenge test in diabetic pregnancy, 99
 - effects on neonates, 675
- Pain, obstetric, mechanisms in, 576-577, 579, 580-581, 601-602
- Palate, cleft, in infants of diabetic mothers, 153
- Pancuronium, in obstetric anesthesia, 570
- Papillomavirus infection, vaginal, 461-481
- Paracervical block in obstetrics, 567, 588-591
- fetal complications from, 590-591
 - maternal complications from, 589-590
 - technique of, 588-589
- Parathyroid gland, function studies in infants of diabetic mothers, 131
- Parity
- and brow presentations, 344
 - and face presentations, 334-335
- Pelvic inflammatory disease
- in actinomycosis, 1236-1237
 - anaerobic and aerobic bacteria in, 1232-1235
 - Chlamydia trachomatis* in, 1235-1236
 - epidemiology of, 1230-1232
 - hysterectomy in, 1231
 - incidence of, 1230
 - late sequelae of, 1231-1241
 - and management of pelvic abscess, 1187-1196
 - mycoplasmas in, 1235
 - nongonococcal pathogens in, 1232-1238
 - problems in studies of, 1228-1230
 - in streptococcal infections, 1237-1238
 - treatment of, 1238-1240
 - in tuberculosis, 1237
- Pelvic size
- and brow presentations, 345
 - and face presentations, 335-336
- Pelvimetry, x-ray
- in brow presentations, 348
 - in face presentations, 340-341
- Pentobarbital, in obstetric analgesia, affecting neonates, 652
- Pericardial effusions, in pregnancy, 737
- Pfannenstiel incision, 1179
- pH, vaginal, 360
 - and malodor formation, 373-374
 - in vaginitis, 374, 450
- Phenothiazines, in obstetric analgesia, 599
 - effects on neonates, 656, 657
- Phenylketonuria
- antenatal diagnosis of, 1045-1046
 - maternal, affecting fetus, 858
- Pheochromocytoma, hot flashes with, 232, 235
- Phlebography, in venous thrombosis of pregnancy, 765
- Phonocardiography, in pregnancy, 712-714
- Phosphatidylcholine in amniotic fluid, and fetal lung maturity, 86, 111
- Phosphatidylglycerol in amniotic fluid, 80-84, 136
- Photocoagulation, in diabetic pregnancy with retinopathy, 120
- Photosensitivity, from oral contraceptives, 974

- Pituitary gland
 ablation in diabetic pregnancy with retinopathy, 120
 hormone changes in aging, 175-176
 oral contraceptives affecting, 871-872, 971-972
 tumors from oral contraceptives, 915
- Placenta
 and circulation in fetus, 545-547
 previa, and face presentations, 336
 transfer of drugs in, 555-558
- Plasma volume in pregnancy, 526, 693-697
- Plethysmography, in venous thrombosis of pregnancy, 766
- Podophyllin, in condylomata acuminata, 479-480
- Polycythemia, in infants of diabetic mothers, 134-135
- Polyhydramnios, and face presentations, 336
- Pompe's disease, antenatal diagnosis of, 1047
- Porphyria, oral contraceptives affecting, 974
- Posture, and cardiac output at term, 528-529
- Prednisone provocative test, for glucose intolerance in pregnancy, 14-15
- Pregnancy
 in adolescence, hazards of, 979-980
 angina pectoris in, 785
 antenatal diagnosis of genetic disorders in.
See Antenatal diagnosis of disorders
 anticoagulant drugs in, 813-816, 826
 in pulmonary embolism, 770
 in venous thrombosis, 766-767
 aortic disorders in, 729-731
 aortic valve disorders in, 727-730, 780
 arrhythmias in, 782-783
 treatment of, 809-813
 atrial septal defect in, 732-734
 blood flow in
 regional, 533
 renal, 533, 539
 uterine, 530-533, 556
 blood pressure in, 529, 699
 blood volume in, 526, 693-697
 cardiac output in, 526-529, 697-699
 distribution of, 702-703
 exercise affecting, 705-706
 cardiomyopathy in, 737, 781
 cardiovascular diseases in, 691-865. *See also*
 Cardiovascular disorders, in
 pregnancy
 cardiovascular physiology in, 693-707
 condylomata acuminata in, 481
 diabetes in, 1-162, 675. *See also* Diabetic pregnancy
 Pregnancy (*Continued*)
 digitalis glycosides in, 817-818
 diuretics in, 818-820
 ectopic, hysterectomy in, 1251
 and effects of metronidazole, 415-416, 419-420
 Eisenmenger syndrome in, 732
 endocarditis in, subacute bacterial, 734-735, 784, 828
 exercise in, 704-707
 and fetal health, 706-707
 fat mobilization in, 34-35
 gastrointestinal changes in, 538-539
 glucagon secretion in, 31-32
 glucose assimilation in, 32-34
 heart in, 525-526
 heart failure in, 783-784
 hemorrhoids in, 758-759
 high-risk, obstetric anesthesia in, 671-677
 hypertension in, 781
 pulmonary hypertension, 731-732, 784
 hypotension in, 785
 insulin secretion and insulin response in, 26-31
 lipoprotein lipid metabolism in, 35-38
 Marfan's syndrome in, 729-730, 780, 781
 metabolic changes in, 22-38
 mitral valve disorders in, 722-727, 780
 patent ductus arteriosus in, 735
 pericardial effusions in, 737
 physiologic changes in, 525-540
 and preparation for childbirth, 575-585
 and prosthetic heart valve function, 735, 737, 780
 pulmonary embolism in, 762, 769-770
 pulmonary stenosis in, 731
 renal changes in, 539-540
 respiration in, 703-704
 exercise affecting, 704-705
 respiratory changes in, 533-538
 spider veins in, 759
 strokes in, 825-832. *See also* Cerebrovascular disease, in pregnancy
 subaortic stenosis in, idiopathic hypertrophic, 735-736, 781-782
 tetralogy of Fallot in, 732
 thromboembolic complications of, 784
 varicose veins in, 749-758, 764
 vascular resistance in, 699
 venous disorders in, 749-759
 venous dynamics in, 743-749
 venous thrombosis in, 761-768
 ventricular septal defect in, 734
 weight gain and adipose tissue metabolism in, 22-26

- Premature delivery
 extreme, management of, 677
 general anesthesia in, 629
 regional anesthesia in, 614
- Prenatal diagnosis. *See* Antenatal diagnosis of disorders
- Prepared childbirth, 575-585
 educational materials for, 584-585
 effectiveness of, 582-583
 Lamaze method in, 580-582
 psychoprophylaxis in, 578-580
 effect on neonates, 652
- Read method of natural childbirth in, 576-578
- Presentation
 breech, analgesia in, 523
 face and brow, 333-349
- Procainamide, in arrhythmias in pregnancy, 811
- Progesterone
 challenge test in amenorrhea, 946
 and estrogen production, 199-200
 receptors for, 199
 in breast cancer, 313
 respiratory effects of, 534, 564
- Progestins
 and estrogen production, 199-200
 with estrogen replacement therapy, 213, 248
 in menopausal hot flashes, 238
 in oral contraceptives. *See* Oral contraceptives
- Prolactin levels, in breast cancer, 311
- Promethazine in obstetric analgesia,
 affecting neonates, 652, 657, 659
- Propranolol, in arrhythmias in pregnancy, 812-813
 affecting fetus, 677, 858
- Prostaglandins, and neuroendocrine function, 225-226
- Prosthetic heart valves, function in pregnancy, 735, 737, 780
- Protein
 excretion in pregnancy, 539
 metabolism of, oral contraceptives affecting, 936-939
 in vaginal secretions, 357-359
- Proteinuria, in diabetic nephropathy in pregnancy, 110
- Psychologic symptoms, in menopause, 219-227
 and endocrine dysfunction, 221-227
- Psychoprophylaxis, in prepared childbirth, 578-580
 effects on neonates, 652
- Pudendal block, in obstetrics, 567, 592-594
 fetal complications from, 593
 maternal complications from, 593
 technique of, 592-593
- Pudendal varicosities, in pregnancy, 758
- Pulmonary artery catheter, for hemodynamic monitoring, 795-797
- Pulmonary embolism, in pregnancy, 762, 769-770
- Pulmonary hypertension, in pregnancy, 731-732, 784
- Pulmonic valve stenosis, in pregnancy, 731
- Purpura, thrombotic thrombocytopenic, in pregnancy, 829-830
- Putrescine, in vaginal discharge, 374, 448, 449
- Pyelonephritis, in diabetic pregnancy, 98
- Quinidine, in arrhythmias in pregnancy, 811
- Radiation exposure, breast cancer from, 306
- Radiology
 chest x-ray in pregnancy, 712
 as fetal maturity test, 74
- Radionuclide studies
 cardiac, in pregnancy, 718-721
 in venous thrombosis of pregnancy, 766
- Radiotherapy
 and antenatal diagnosis of fetal disorders, 1034
 in invasive carcinoma of vagina, 511-512
- Rectus femoris muscle flap transposition, 1291-1292
- Refsum's disease, prenatal diagnosis of, 1084
- Regional anesthesia in obstetrics, 565-568, 587-594, 602-616
 in abnormal patients, 613-616
 complications from, 606-613
 in diabetes, 615
 effects on labor, 611-612
 effects on neonates, 656
 failure of, 609-611
 in fetal distress, 614
 headache from, 607
 in heart disease, 615-616
 in hemorrhage, 615
 in hypertension, 614
 hypotension from, 603, 606
 neurologic disorders from, 613
 in prematurity, 614
 respiratory insufficiency from, 606-607
 techniques with, 602-606
 in toxemia, 613-614
 toxic reactions to, 607-608
- Renal vein thrombosis, in infants of diabetic mothers, 135
- Respiration, in pregnancy, 703-704
 exercise affecting, 704-705

- Respiratory distress syndrome, in infants of diabetic mothers, 136-139
treatment of, 138-139
- Respiratory system**
fetal, 549-552, 636-637
drugs affecting, 672
insufficiency from regional anesthesia, 606-607
in pregnancy, 533-538
- Resuscitation** of newborn, 635-647, 673
and Apgar scoring system, 640-643
and causes of neonatal depression, 639-640
drug therapy in, 644-645
equipment for, 643-644
in hypotension, 645-646
in meconium aspiration, 646-647
principles of, 640
- Retinal vascular occlusion**, from oral contraceptives, 956
- Retinopathy**, in diabetic pregnancy, 116-121
nephropathy with, 110
- Rh sensitization, as amniocentesis risk, 1013-1015
- Rheumatoid arthritis**, oral contraceptives affecting, 970
- Ritodrine in pregnancy, affecting infant, 676
- Rubella** in pregnancy, affecting fetus, 858, 859
- Sacropexy**, abdominal, for vaginal vault prolapse, 1217-1225
- Sarcoma of vagina**, 507
- Sartorius muscle flap transposition**, 1280
- Sclerosis**, multiple, oral contraceptives affecting, 970
- Scopolamine, in obstetric analgesia, 571, 599
- Secobarbital for obstetric analgesia, affecting neonates, 653, 656, 657
- Semen**, affecting vaginal odor, 374
- Serotonin**
metabolism affected by estrogens, 225
as neurotransmitter, 222
- Sex hormone-binding globulin**
estradiol bound to, 188
mestranol affecting, 211
plasma levels in breast cancer, 308-310
testosterone bound to, 186
- Sex hormones** in pregnancy, affecting fetus, 858
- Sexual activity**
in adolescence, 977-979
vaginal fluid composition in, 370-373
- Shake test** of amniotic fluid, 78-79
- Sickle cell disease**
antenatal diagnosis of, 1060
oral contraceptives affecting, 973
in pregnancy, 829
screening program for, 1061-1062
- Sjogren-Larsson syndrome**, prenatal diagnosis of, 1080
- Skeletal system**
anomalies in infants of diabetic mothers, 151-152
bone loss in menopause, 203-217
estrogen therapy in, 269-272
changes with age, 173
ultrasonic diagnosis of anomalies, antenatal, 1118
- Skin**
changes from oral contraceptives, 973-974
hereditary disorders of, prenatal diagnosis of, 1069-1086
- Skin sampling**, fetal, 1072-1079
- Smoking**, and effects of oral contraceptives, 895, 896, 897, 959-960
- Sodium levels**, maternal, affecting infant, 674
- Sphingomyelin** ratio to lecithin, in amniotic fluid, 75-78, 551-552
- Spider veins**, in pregnancy, 759
- Spina bifida**
and α -fetoprotein in amniotic fluid, 1089-1091
ultrasonic diagnosis of, antenatal, 1109
- Spinal anesthesia** in obstetrics, 567, 602-603
effects on labor, 611-612
effects on neonates, 661, 662
failure of, 609
neurologic complications from, 613
- Sterilization**, hysterectomy in, 1253-1254
- Steroid hormones**, in amniotic fluid, 1046
- Streptococcal infections**, and pelvic inflammatory disease, 1237-1238
- Streptokinase** in pregnancy
in pulmonary embolism, 770
in venous thrombosis, 767-768
- Strokes**. *See* Cerebrovascular disease
- Subaortic stenosis**, idiopathic hypertrophic, in pregnancy, 735-736, 781-782
- Subarachnoid hemorrhage**, in pregnancy, 832
- Succinic acid ratio to lactic acid**, in vaginitis, 447-448
- Succinylcholine**, in obstetric anesthesia, 570
- Sulfonamide cream**, in *Gardnerella vaginalis* infection, 454-455
- Surfactant**, pulmonary, in test for fetal maturity, 78
- Surgery**
abdominal incisions in, 1176-1180
transverse, 1179-1180
vertical, 1177-1179
cesarean section. *See* Cesarean section and indications for hysterectomy, 1245-1258. *See also* Hysterectomy
intraoperative considerations in, 1180-1181

- Surgery (Continued)**
- muscle and musculocutaneous flaps in, 1277-1316
 - gracilis, 1280-1282
 - principles of, 1278-1279
 - rectus femoris, 1291-1292
 - sartorius, 1280
 - tensor fascia lata, 1282-1291
 - and pelvic abscess management, 1187-1196
 - preparation of patient for, 1175-1176
 - in pulmonary embolism of pregnancy, 770
 - and risks from oral contraceptives, 960
 - sacropexy for vaginal vault prolapse, 1217-1225
 - suture material in, 1181-1183
 - urinary tract injuries in, 1267-1276
 - uterine unification procedures, 1199-1214
 - in venous thrombosis of pregnancy, 768
 - wound closure in, 1181-1183
 - wound dehiscence in, 1184
- Suture material, in gynecologic surgery, 1181-1183**
- Sympathetic block, lumbar, in obstetrics, 567**
- Takayasu's disease, in pregnancy, 829**
- Tamoxifen, in breast cancer, 314**
- Tampons**
- and toxic shock syndrome, 402-404
 - vaginal mucosal alterations from, 396-402
 - vaginal ulcers from, 395-396
- Tay-Sachs disease, antenatal diagnosis of, 1047, 1049**
- Temperature of body**
- in menopausal hot flashes, 233
 - neonatal regulation of, 637-638, 673-674
- Tensor fascia lata muscle flap transposition, 1282-1291**
- Teratogenic agents, cardiac malformations from, 857-859**
- Teratogenic risk, in infants of diabetic mothers, 42-44, 140-141, 149-156**
- Testosterone**
- aging affecting levels of
 - in females, 186-187
 - in males, 176-177
 - conversion to estradiol, 189, 194
 - postmenopausal secretion of, 257
- Tetracaine, for spinal anesthesia, 567, 603**
- effects on neonates, 661, 662
- Tetracycline, in *Gardnerella vaginalis* infection, 455**
- Tetralogy of Fallot, in pregnancy, 732**
- Thalassemia**
- antenatal diagnosis of, 1050, 1056-1057
 - screening program for, 1061-1062
- Thermoregulation, neonatal, 637-638, 673-674**
- Thiazide diuretics, in pregnancy, 818-820**
- Thiopental, in obstetric anesthesia, 561-562**
- effects on neonates, 660, 661
- Thrombocytopenic purpura, thrombotic, in pregnancy, 829-830**
- Thromboembolism**
- development after estrogen therapy, 276-277
 - from oral contraceptives, 895-896, 952-953
 - in pregnancy, 784
- Thrombolytic therapy in pregnancy in pulmonary embolism, 770**
- in venous thrombosis, 767-768**
- Thrombosis, venous**
- in pregnancy, 761-768, 784
 - cerebral vein, 830-831
 - diagnosis of, 765-766
 - epidemiology of, 761-763
 - pathophysiology of, 763-765
 - phlebography in, 765
 - plethysmography in, 766
 - prophylaxis in, 768
 - radioiodine-labeled fibrinogen scanning in, 766
 - treatment of, 766-768
 - ultrasonography in, 765-766
 - of renal vein, in infants of diabetic mothers, 135
- Thymus, and aging of immune system, 171**
- Thyroid disease, oral contraceptives affecting, 971**
- Thyroid hormones**
- activity in aging, 175
 - in amniotic fluid, 1046
 - and breast cancer, 311-312
- Thyroxine, and breast development, 302**
- Tocolytic agents, affecting infant, 676-677**
- Toxemia of pregnancy**
- general anesthesia in, 628-629
 - regional anesthesia in, 613-614
- Toxic shock syndrome, 402-404**
- Transplantation of kidney, diabetic pregnancy after, 114**
- Trichomonas vaginalis***
- cervicitis from, 420, 437
 - vaginitis from, 412-420, 455-456
 - clinical features of, 412-416
 - diagnosis of, 416-418
 - treatment of, 418-420, 437
- Trichothiodystrophy, prenatal diagnosis of, 1083**
- Triglyceride metabolism**
- oral contraceptives affecting, 933
 - in pregnancy, 35-38
 - in diabetic pregnancy, 40-41

- Trisomy syndromes**
 antenatal diagnosis of Down's syndrome, 1025-1029
 cardiac disease in, 859
- Trophoblastic disease, hysterectomy in**, 1252
- Tryptophan metabolism**, 224
 estrogens affecting, 225
- Tuberculosis**, pelvic inflammatory disease in, 1237
- Tuberous sclerosis**, prenatal diagnosis of, 1086
- d-Tubocurarine**, in obstetric anesthesia, 570
- Tumors**
 of breast. *See* Breast, cancer of
 cervical cancer
 hysterectomy in, 1251-1252
 postmenopausal bleeding in, 286, 287
 choriocarcinoma
 cerebral metastases in, 830
 oral contraceptives affecting, 923
endometrial. *See* Endometrium, carcinoma of
 from oral contraceptives, 903-923
 uterine
 hysterectomy in, 1250, 1251-1252
 and postmenopausal bleeding, 286, 287,
 290, 296
 vaginal
 carcinoma in situ, 485-498
 invasive tumors, 503-514
- Twin pregnancies**
 amniocentesis in, 1016-1017
 delivery of, analgesia and anesthesia in, 523
 in diabetic pregnancy, 153
- Ulcers, vaginal**, 408
 from tampons, 395-396
- Ultrasonography**
 fetal
 and amniocentesis, 1009, 1015-1016,
 1106-1108
 in anencephaly, 1110
 in antenatal diagnosis of defects, 1093,
 1103-1120
 for cardiac anatomy, 837-842
 in diabetic pregnancy, 100
 and α -fetoprotein in maternal serum,
 1103-1106
 in gastrointestinal anomalies, 1114-1116
 in hydrocephalus, 1110-1113
 for maturity assessment, 75
 in microcephaly, 1113-1114
 in skeletal dysplasia, 1118
 in spina bifida, 1109
 in urinary tract disorders, 1116-1118
 for vascular dynamics, 842-847
- in pregnancy**
 in cardiac disorders, 714-718, 786
 in venous thrombosis, 765-766
- Umbilical arteries**
 blood velocity waveforms from, 845-847
 single, in infants of diabetic mothers, 153
- Urea**, in vaginal fluids, 369, 371
- Urethra**, atrophic changes in menopause,
 estrogen therapy in, 268-269
- Urinary tract**
 infections from oral contraceptives, 972-973
 operative injuries to, 1267-1276
 anatomic factors in, 1267-1271
 in bladder, 1275-1276
 management of, 1274-1276
 prevention of, 1271-1272
 ureteral, 1273-1274
 ultrasonic diagnosis of disorders, antenatal,
 1116-1118
- Urokinase in pregnancy**
 in pulmonary embolism, 770
 in venous thrombosis, 767-768
- Urticaria**, oral contraceptives affecting, 971
- Uterus**
 abnormalities from DES exposure, 381-386
 blood flow in pregnancy, 530-533, 556
 cervical changes from oral contraceptives,
 918-922
 cervical mucus affected by oral contraceptives, 873
 cervicitis, 420-424
 dilation and curettage of, in postmenopausal bleeding, 286-287, 289, 296
 dysfunctional bleeding in, estrogen therapy in, 275
endometrial hyperplasia of. *See* Endometrium, hyperplasia of
 endometrial tumors from oral contraceptives, 915-918
 endometrium affected by oral contraceptives, 874-875
 estrogen in endometrium, 197-200
 indications for hysterectomy, 1245-1258.
See also Hysterectomy
 relaxation from general anesthesia, 627
 tumors of, and postmenopausal bleeding, 286
 unification procedures, 1199-1214
- Vaccine therapy**, in condylomata acuminata, 480
- Vagina**
 adenocarcinoma of, 506-507
 from DES exposure, 386-388
 adenosis of
 and carcinoma in situ, 495
 from DES exposure, 381
 anaerobic organisms in, 361
 in nonspecific vaginitis, 446-447
 artificial, transudate production in, 371

- Vagina (*Continued*)
 atrophy in menopause
 bleeding with, 286, 297
 estrogen therapy in, 267-268
 carcinoma *in situ*, 485-498
 histopathology in, 488-490, 496
 incidence of, 486
 pathogenesis of, 486-487
 pathology of, 487-490
 symptoms of, 487
 treatment of, 490-495
 cellular desquamate from, 357
 condylomata acuminata of, 461-481
 DES-related lesions of, 379-393. *See also*
 Diethylstilbestrol exposure
 in utero
 discharge from
 infections with, 407-437
 mucoid or epithelial, 430-432, 437
 endodermal sinus tumors of, 507
 endometriosis of, 495
 fistulas of, 408
 invasive tumors of, 503-514
 diagnosis of, 508-511
 pathology of, 504-508
 treatment of, 511-514
 lymphatic drainage of, 505-506
 melanomas of, 507-508
 microbiology of, 360-361, 369, 446
 mucorrhea in, 430-432, 437
 odors from, 361-370
 cyclic variations in, 365-366
 malodors, 373-375
 as sexual attractants, 363, 365
 sexual stimulation affecting, 370-373
 in vaginitis, 374-375, 448, 450
 pH of, 360
 and malodor formation, 373-374
 in vaginitis, 374, 450
 sarcoma of, 507
 secretions of, 355-375
 aliphatic acids in, 364, 447
 amines in, in nonspecific vaginitis, 448
 amino acids and proteins in, 357-359
 cadaverine in, 448, 449
 carbohydrates in, 359-360
 cyclic changes in, 356-357
 excessive, 430-432
 glycogen in, 360, 369
 high molecular weight constituents of, 356-357
 lactic acid in, 360, 365, 369, 447
 low molecular weight compounds in, 361-370
 organic constituents of, 364-366
 putrescine in, 374, 448, 449
- Vagina, secretions of (*Continued*)
 quantitation of, 355-356
 sexual stimulation affecting, 370-373
 succinic acid in, in nonspecific vaginitis, 447-448
 tampons affecting, 395-405
 ulcers of, 408
 from tampons, 395-396
 vault prolapse in, repair of, 1217-1225
 Vaginectomy, in carcinoma *in situ*, 491
 Vaginitis, 407-437
 atrophic, 407, 432-434
 clinical features of, 432-433
 diagnosis of, 433
 treatment of, 433-434, 437
 in candidiasis, 424-430
 desquamative inflammatory, 408
 treatment of, 437
 emphysematosa, 408
 treatment of, 437
 in *Gardnerella vaginalis* infection, 374, 407, 411-412, 439-458
 nonspecific, 439-458
 oral contraceptives affecting, 973
 treatment of, 434-437
 in *Trichomonas vaginalis* infection, 412-420
 vaginal odor in, 374-375, 448, 450
 Vaporizers, for inhalation analgesia, 620-621
 Varicose veins in pregnancy, 749-758, 764
 complications of, 757-758
 treatment of, 754-757
 vulvar and pudendal, 758
 Vasculature
 disease of, in diabetic pregnancy, 107-121
 fetal dynamics in, ultrasonographic evaluation of, 842-847
 oral contraceptives affecting, 951-962
 in pregnancy, 533
 resistance in, 699
 pulmonary, in fetus, 548, 636
 drugs affecting, 672
 uterine, in pregnancy, 532
 Vectorcardiography in pregnancy, 712
 Venous disorders in pregnancy, 749-759
 thrombosis, 761-768, 784
 Venous dynamics in pregnancy, 743-749
 Ventricular septal defect, in pregnancy, 734
 Vinbarbital in obstetric analgesia, affecting neonates, 651-652
 Virus infections
 cervicitis from herpes simplex, 420, 437
 vaginal condylomata acuminata, 461-481
 Viscosity of blood, in infants of diabetic mothers, 134
 Vitamin D metabolites, in infants of diabetic mothers, 133

Vulva

atrophic changes in menopause, estrogen therapy in, 267-268
varicosities in pregnancy, 758

Vulvovaginitis

in candidiasis, 424-430
vaginal odor in, 374

Warfarin in pregnancy

affecting fetus, 826, 858
contraindications to, 784
in venous thrombosis, 767

Weight

changes in diabetic pregnancy, 38-39

Weight (Continued)

changes from oral contraceptives, 890-891
gain in pregnancy, 22-26
macrosomia in infants of diabetic mothers, 41-42, 94, 139-140
obesity, and binding capacity of sex hormone-binding globulin, 308-310
Wilson's disease, oral contraceptives affecting, 968
Wiskott-Aldrich syndrome, prenatal diagnosis of, 1082
Xeroderma pigmentosum, antenatal diagnosis of, 1032, 1081

